Sex differences in circulating inflammatory mediators as a function of substance use disorder.
Adult
Anxiety Disorders
/ blood
Biomarkers
/ blood
Body Mass Index
C-Reactive Protein
/ metabolism
Depressive Disorder, Major
/ blood
Female
Humans
Inflammation
Inflammation Mediators
/ blood
Interleukin-10
/ blood
Interleukin-6
/ blood
Interleukin-8
/ blood
Male
Middle Aged
Psychopathology
Sex Factors
Substance-Related Disorders
/ blood
Tumor Necrosis Factor-alpha
C-reactive protein
Chemokines
Cytokines
Depression
Inflammation
Interleukin-10
Interleukin-8
Substance use disorder
Tumor necrosis factor-alpha
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
07
10
2020
revised:
20
01
2021
accepted:
23
01
2021
pubmed:
26
2
2021
medline:
2
7
2021
entrez:
25
2
2021
Statut:
ppublish
Résumé
Substance use disorders (SUD) with comorbid depression and anxiety are linked to poor treatment outcome and relapse. Although some depressed individuals exhibit elevated blood-based inflammation (interleukin-6 [IL-6] and C reactive protein [CRP]), few studies have examined whether the presence of SUD exacerbates inflammation. Treatment-seeking individuals with major depressive disorder (MDD), anxiety disorders, and/or SUD (N = 160; 80 % with MDD) recruited into the Tulsa 1000 study provided blood samples, participated in clinical interviews, and completed a questionnaire battery querying symptoms of current psychopathology and emotional processing. Analyses followed a multistep process. First, groups were created on the presence versus absence of 1+ lifetime SUD diagnoses: SUD+ (37 F, 43 M) and SUD- (60 F, 20 M). Second, a principal component analysis (PCA) of questionnaire data resulted in two factors, one indexing negative emotionality/withdrawal motivation and one measuring positive emotionality/approach motivation. Third, SUD groups, extracted PCA factors, and nuisance covariates (age, body mass index [BMI], nicotine use, psychotropic medication [and hormone/contraception use in females]) were entered as simultaneous predictors of blood-based inflammation (IL-6, IL-8, IL-10, tumor necrosis factor-α, and CRP). Within females, SUD + exhibited higher IL-8 and IL-10 but lower CRP levels than SUD-. In contrast, SUD was not associated with biomarker levels in males. Across sexes, higher BMI was linked to higher IL-6 and CRP levels, and within the five biomarkers, IL-6 and CRP shared the most variance. These findings point to sex-specific inflammatory profiles as a function of SUD that may provide new targets for intervention.
Sections du résumé
BACKGROUND
Substance use disorders (SUD) with comorbid depression and anxiety are linked to poor treatment outcome and relapse. Although some depressed individuals exhibit elevated blood-based inflammation (interleukin-6 [IL-6] and C reactive protein [CRP]), few studies have examined whether the presence of SUD exacerbates inflammation.
METHODS
Treatment-seeking individuals with major depressive disorder (MDD), anxiety disorders, and/or SUD (N = 160; 80 % with MDD) recruited into the Tulsa 1000 study provided blood samples, participated in clinical interviews, and completed a questionnaire battery querying symptoms of current psychopathology and emotional processing. Analyses followed a multistep process. First, groups were created on the presence versus absence of 1+ lifetime SUD diagnoses: SUD+ (37 F, 43 M) and SUD- (60 F, 20 M). Second, a principal component analysis (PCA) of questionnaire data resulted in two factors, one indexing negative emotionality/withdrawal motivation and one measuring positive emotionality/approach motivation. Third, SUD groups, extracted PCA factors, and nuisance covariates (age, body mass index [BMI], nicotine use, psychotropic medication [and hormone/contraception use in females]) were entered as simultaneous predictors of blood-based inflammation (IL-6, IL-8, IL-10, tumor necrosis factor-α, and CRP).
RESULTS
Within females, SUD + exhibited higher IL-8 and IL-10 but lower CRP levels than SUD-. In contrast, SUD was not associated with biomarker levels in males. Across sexes, higher BMI was linked to higher IL-6 and CRP levels, and within the five biomarkers, IL-6 and CRP shared the most variance.
CONCLUSION
These findings point to sex-specific inflammatory profiles as a function of SUD that may provide new targets for intervention.
Identifiants
pubmed: 33631550
pii: S0376-8716(21)00105-8
doi: 10.1016/j.drugalcdep.2021.108610
pmc: PMC8026624
mid: NIHMS1676603
pii:
doi:
Substances chimiques
Biomarkers
0
IL10 protein, human
0
Inflammation Mediators
0
Interleukin-6
0
Interleukin-8
0
Tumor Necrosis Factor-alpha
0
Interleukin-10
130068-27-8
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108610Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM121312
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA050677
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH113871
Pays : United States
Organisme : NIAAA NIH HHS
ID : F31 AA027169
Pays : United States
Organisme : NIMHD NIH HHS
ID : K99 MD015736
Pays : United States
Organisme : NIMHD NIH HHS
ID : R00 MD015736
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Front Psychiatry. 2017 Jun 16;8:108
pubmed: 28670290
Assessment. 2011 Sep;18(3):263-83
pubmed: 21697139
Psychol Assess. 2007 Jun;19(2):176-88
pubmed: 17563199
Brain Behav Immun. 2018 Jan;67:130-138
pubmed: 28813640
Hum Psychopharmacol. 2017 Sep;32(5):
pubmed: 28750478
PLoS One. 2012;7(11):e48230
pubmed: 23133619
Alcohol. 2020 Jun;85:35-40
pubmed: 31610228
Brain Behav Immun. 2018 Oct;73:85-114
pubmed: 29928963
Addiction. 2005 Jun;100(6):787-96
pubmed: 15918809
BMC Psychiatry. 2006 Oct 20;6:44
pubmed: 17054775
Neuropsychopharmacology. 2020 May;45(6):998-1007
pubmed: 31940661
J Neurosci. 2011 Dec 7;31(49):17835-47
pubmed: 22159099
JMIR Ment Health. 2020 Jan 28;7(1):e16919
pubmed: 32012081
Neurotox Res. 2013 Feb;23(2):174-88
pubmed: 22714667
Neurosci Biobehav Rev. 2016 May;64:148-66
pubmed: 26915929
Neurosci Biobehav Rev. 2011 Jan;35(3):537-55
pubmed: 20603146
J Neurosci. 2011 Apr 20;31(16):5942-55
pubmed: 21508219
Neuropsychopharmacology. 2017 Jan;42(1):216-241
pubmed: 27480574
Neuropsychopharmacology. 2019 Jan;44(1):184-199
pubmed: 29955150
J Stud Alcohol. 1998 Jul;59(4):427-38
pubmed: 9647425
Mol Psychiatry. 2016 Dec;21(12):1696-1709
pubmed: 26903267
J Immunol. 2008 May 1;180(9):5771-7
pubmed: 18424693
J Affect Disord. 2012 Aug;139(3):230-9
pubmed: 21872339
Lancet Infect Dis. 2006 Sep;6(9):557-69
pubmed: 16931407
Brain Behav Immun. 2018 Jan;67:59-64
pubmed: 28867283
Front Psychiatry. 2015 Feb 16;6:17
pubmed: 25762940
Crit Rev Immunol. 2012;32(1):23-63
pubmed: 22428854
Psychoneuroendocrinology. 2019 Apr;102:16-23
pubmed: 30496908
PLoS One. 2014 Feb 06;9(2):e88196
pubmed: 24516611
Harv Rev Psychiatry. 2009;17(2):103-19
pubmed: 19373619
Neurosci Biobehav Rev. 2017 Dec;83:97-108
pubmed: 28986182
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
J Affect Disord. 2018 Jul;234:139-147
pubmed: 29529546
J Psychosom Res. 1994 Jan;38(1):23-32
pubmed: 8126686
Compr Psychiatry. 2012 Aug;53(6):657-65
pubmed: 22152496
ACS Chem Neurosci. 2015 Apr 15;6(4):522-5
pubmed: 25734247
Mol Psychiatry. 2016 Oct;21(10):1358-65
pubmed: 26552591
J Psychiatr Res. 2014 Nov;58:36-45
pubmed: 25088287
Brain Behav Immun. 2020 Aug;88:631-639
pubmed: 32380271
Biol Psychiatry. 2010 Oct 15;68(8):748-54
pubmed: 20719303
Brain Behav Immun. 2011 Aug;25(6):1223-32
pubmed: 21447380
Neuropsychopharmacology. 2015 Jun;40(7):1709-16
pubmed: 25598426
Brain Behav Immun. 2013 Mar;29:136-146
pubmed: 23305936
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Brain Behav Immun. 2018 May;70:61-75
pubmed: 29499302
Psychoneuroendocrinology. 2013 Oct;38(10):2209-17
pubmed: 23711900
Arch Immunol Ther Exp (Warsz). 1976;24(6):799-805
pubmed: 65164
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Apr 20;83:86-91
pubmed: 29309829
Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 Jul;4(7):619-626
pubmed: 31103547
Biol Psychiatry. 2010 Mar 1;67(5):446-57
pubmed: 20015486
JAMA Psychiatry. 2018 Feb 1;75(2):201-209
pubmed: 29197929
Am J Ther. 2004 Sep-Oct;11(5):354-65
pubmed: 15356431
Innate Immun. 2017 Jul;23(5):432-439
pubmed: 28443392
Annu Rev Immunol. 2001;19:683-765
pubmed: 11244051
Lancet. 1998 Mar 28;351(9107):950-3
pubmed: 9734942
Lupus. 2011 May;20(6):620-7
pubmed: 21558138
J Pharmacol Exp Ther. 1989 Aug;250(2):606-10
pubmed: 2788218
J Trauma Stress. 1994 Apr;7(2):289-302
pubmed: 8012748
Transl Psychiatry. 2013 Apr 23;3:e249
pubmed: 23612048
Neuropharmacology. 2018 Jul 15;137:211-220
pubmed: 29723540
BMJ Open. 2018 Jan 24;8(1):e016620
pubmed: 29371263
Transl Psychiatry. 2012 Nov 20;2:e196
pubmed: 23168996
Brain Behav Immun. 2006 Jan;20(1):80-91
pubmed: 16039825
Alcohol Clin Exp Res. 2002 Dec;26(12):1872-9
pubmed: 12500112
Biometrika. 1950 Dec;37(3-4):409-28
pubmed: 14801065
Drug Alcohol Depend. 2013 Dec 1;133(2):712-7
pubmed: 24099969
J Neuroimmunol. 2018 May 15;318:80-86
pubmed: 29500107
Drug Alcohol Depend. 2015 Sep 1;154:1-13
pubmed: 26072219
Brain Behav Immun. 2020 Oct;89:501-512
pubmed: 32805393
Physiol Behav. 2018 Feb 1;184:108-115
pubmed: 29133231
Pharmacol Ther. 2013 Aug;139(2):289-300
pubmed: 23631821
World J Gastroenterol. 2010 Mar 21;16(11):1304-13
pubmed: 20238396
Neurobiol Stress. 2019 May 25;11:100177
pubmed: 31304198
Addiction. 2020 Dec;115(12):2257-2267
pubmed: 32533781
Biol Psychiatry. 2007 Dec 1;62(11):1324-33
pubmed: 17678633
Acta Psychiatr Scand. 2017 May;135(5):373-387
pubmed: 28122130
J Affect Disord. 2019 Mar 15;247:57-65
pubmed: 30654266
J Infect Dis. 2000 Jan;181(1):176-80
pubmed: 10608764
PLoS One. 2018 Jun 1;13(6):e0197267
pubmed: 29856741